Search results
Results from the WOW.Com Content Network
Astellas Pharma office in Canada. Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 ...
Enfant Philippines Consumer goods Apparel retailers Manila: 1995 Baby goods and apparel P A ePLDT Ventus: Industrials Business support services Makati: 2001 Contact centers P A Fil-Asian Airways: Consumer services Airlines Cebu: 2011 Airline, defunct 2014 P D Filinvest: Conglomerates - Taguig: 1955 Real estate, hotels, tourism, banking P A
Astellas Pharma, a multinational pharmaceutical company of Japan, and part of the Mitsubishi UFJ Financial Group conglomerate. Pages in category "Astellas Pharma" The following 27 pages are in this category, out of 27 total.
Get answers to your AOL Mail, login, Desktop Gold, AOL app, password and subscription questions. Find the support options to contact customer care by email, chat, or phone number.
Daiichi Sankyo was established in 2005 through the merger of Sankyo Company, Limited (三共株式会社, Sankyō Kabushiki Kaisha) and Daiichi Pharmaceutical Company, Limited (第一製薬株式会社, Daiichi Seiyaku Kabushiki Kaisha), which were century-old pharmaceutical companies based in Japan.
Name Headquarters Accenture: Mandaluyong [1]: Acer: Manila [2]: Apple: Makati Asus: Pasig Canon: Taguig [3]: Cisco Systems: Makati [4]: Cloudwalk Digital: Quezon City ...
Since then, the company has established subsidiaries in Europe (1971), South America, China, India, Philippines, Vietnam, Thailand and Australia. The company later expanded its product range to include coronary stents and catheters , and acquired, among others, the cardiovascular specialty companies Vascutek and Microvention in 2002 and 2006 ...
Bendamustine received its first marketing approval in Germany, where it is marketed under the tradename Ribomustin, by Astellas Pharma GmbH's licensee, Mundipharma International Corporation Limited. It is indicated as a single-agent or in combination with other anti-cancer agents for indolent non-Hodgkin's lymphoma , multiple myeloma, and ...